FDA approves Nelkarmi for pretreated ALK+ NSCLC

AI SummaryClose X

GSK received FDA accelerated approval for Nelkarmi (neladalkib) for previously‑treated advanced ALK+ NSCLC ahead of the 27 November 2026 target date based on the phase I/II ALKOVE‑1 primary analysis of 222 patients (trial enrolled 700). Confirmed ORR was 49% (33/67; 95% CI 37–62%) in patients after alectinib and 32% (50/155; 95% CI 24–40%) in patients with ≥2 prior ALK TKIs plus chemotherapy; DOR ≥6 months occurred in 76% and 69% of responders and ≥12 months in 52% and 51% respectively. Intracranial ORR was 55% (11/20; 25% CR) and 26% (14/53; 11% CR). Permanent discontinuation due to adverse reactions was 5%, with hepatotoxicity most frequent.

Disclaimer*

Companies

GSK (GSK)
UK 100

Latest directors dealings